151 results about "Tissue inflammation" patented technology

The present invention relates to methods for treating inflammation in body tissues. More specifically, certain disclosed methods relate to selectively inducing apoptosis in inflammatory immune cells by heating cells for a sufficient time and at a sufficient temperature to induce programmed cell death. The disclosed stents can be placed in contact with the inflammatory cells and heated under controlled conditions. The disclosed apparatus and methods are particularly suitable for treating athersclerotic plaques.

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A_2A adenosine receptor agonist. If no anti-pathogenic agent is known the A_2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.

The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.

The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.

There is disclosed a method for treating dermatologic diseases caused by microbial overgrowth or inflammation, such as psoriasis, fungal infections, eczema, dandruff, acne, genital herpes lesions, and leg ulcers. There is further disclosed an antiviral lubricating composition that is effective in preventing the transmission of the HIV virus and other sexually transmitted diseases. There is also disclosed systemic and anti-inflammatory compositions and formulations and a method for reducing tissue inflammation in tissues such as the bowel, muscle, bone, tendon and joints (e.g., arthritis).

The present invention relates to non-psychoactive derivatives of tetrahydro-cannabinol, which exhibit anti-inflammatory and analgesic activities. In particular, the present invention relates to methods of administering the derivatives and pharmaceutical compositions as therapeutic agents in the treatment of pain and tissue inflammation.

The invention discloses an application of an adipose-derived mesenchymal stem cell (ADSC) exosome in preparation of medicines for treating adipose tissue inflammations. The adipose-derived mesenchymal stem cell exosome is prepared by the following method: (1) dispersing stripped adipose tissues in digestive juice so as to produce cell suspension; (2) centrifuging the cell suspension so as to form a cell precipitate, separating the precipitate, and washing so as to obtain adipose tissue matrix cells containing the adipose-derived mesenchymal stem cells; and (3) performing multiplication culture on the ADSC in an in-vitro culture system, collecting the supernatant subjected to multiplication culture for concentrating, adding an exosome extraction reagent into the concentrated supernatant, thereby obtaining the ADSC exosome. The ADSC exosome can achieve the effects of inhibiting infiltration and activation of abdominal adipose tissue macrophages and inhibiting production and release of proinflammatory cytokine and has an excellent effect of inhibiting the adipose tissue inflammations.

The invention comprises use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium and a mixture of any thereof in the manufacture of a food product, dietary supplement or medicament for lowering tissue inflammation (in particular, adipose, liver or muscle tissue inflammation) and treating cardiovascular disease in a mammal. The lactic acid bacteria and/or Bifidobacteria can also be used to treat diabetes and insulin resistance and induce enhanced secretion of insulin upon a glucose challenge and lower blood glucose levels without a concomitant decrease in weight gain.

Therapeutic and cosmetic treatments are performed through the application of azelaic acid ester compositions to patients suffering from or exhibiting tissue inflammation. The diagnosis, characterization and treatment of a patient suffering from or exhibiting tissue inflammation may be enhanced by using selected proteinaceous biomarkers obtained from analysis of said markers by means of multiplexed immunoassay and comparison to the biomarker levels of healthy tissue.

A dispersing tablet of glabrous sarcandra herb for treating pneumonia, appendicitis, cellular tissue inflammation, cancer, etc is prepared from the dried extract of glabrous sarcandra herb through pulverizing and mixing with auxiliary.

The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light.

The invention provides a thermo-sensitive gelatin preparation for endometrium stem cells. The thermo-sensitive gelatin preparation comprises an endometrium stem cell cellular preparation, an endometrium stem cell exosome preparation, chitosan, mannitol, hyaluronic acid, sodium alginate and beta-sodium glycerophosphate. The thermo-sensitive gelatin preparation is free from puncturing and recyclingand only needs to be transmitted into the lumina of an external genital system of women, the thermo-sensitive gelatin is cross-linked to form a semisolid preparation being in complete cooperation withthe shape of the lumina, the repair effect can be achieved, and repeated damage to organisms can be avoided. After being applied, the composite preparation can gradually dissolve through the temperature of human bodies to form a solution, mesenchymal stem cells in the preparation are released, and through polarization, cambium is obtained. Thermo-sensitive gelatincell factors in the preparation can be released slowly, and the defect of massive running off of the cells after recycling is performed can be overcome. The active factors secreted by the stem cells can restrain tissue inflammation,improve the regeneration capacity of tissue and promote repair of original tissue, and can achieve the effect of wound repair.

A method for treating a mammal having oral tissue inflammation is provided, where the inflamed oral tissue is contacted with a safe, efficacious, non-irritating oral composition having an anti-inflammatory agent comprising a magnolia extract. The magnolia anti-inflammatory active ingredient reduces one or more mediators of inflammation and reduces inflammation in oral tissue. The oral composition can be in the form of a mouth rinse; dentifrice, including toothpaste, gels, powders, lozenges; medicament gel; animal products; and the like.

A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.

Disclosed in the present invention is the composition for reducing local fat and body weight, and pharmaceuticals and use thereof. The composition contains resveratrol and curcumin extract at a weight ration from 1:30 to 10:1. The composition and pharmaceuticals thereof of the invention can inhibit the growth of fat cells, cause planned apoptosis of fat cells, achieve the effects of reducing fat cells, and reducing local fat deposition and body weight without causing inflammations or necrosis of surrounding cells or tissues and inflammations or pain reactions of surrounding tissues, thereby avoiding the problems of tissue damage and inflammatory pains caused by liposuction or low invasion fat-dissolving apparatus used in the prior art and the problems such as surrounding tissue inflammations and necrosis infections triggered by cell disruption and necrosis caused by components of a fat-dissolving injection, phosphatidylcholine or sodium deoxycholate.

The invention relates to the technical field of traditional Chinese medicine and concretely relates to a drug of traditional Chinese medicine for remedying skin disease and the preparation method and application of the drug. The drug of the invention is prepared by the raw materials of a rhubarb, a dried tangerine peel, a liquorice and a coptis chinensis. The drugs of the raw materials have good curative effect within the following weight range of 3 to 6 portions of the rhubarbs, 2 to 5 portions of the dried tangerine peels, 3 to 6 portions of the liquorice and 1 to 5 portions of the coptis chinensis. The drug of the invention has the functions of clearing heat and toxin, clearing fire, cooling blood, activating blood, dispersing tiredness, detumescence, acesodyne, removing putrefaction, generating muscle, diminishing inflammation and resisting bacteria and is used for remedying the furuncle, the carbuncle, the honeycomb-shaped tissue inflammation, the acne, the bedsore, the boil, the eczema, the strip-shaped herpes, the simplex herpes and the burn and scald with significant curative effect.